In-stent restenosis is a major problem following coronary stent implantation, and inflammation plays an active role. We evaluated the effectiveness of the inflammatory marker C-reactive protein (CRP) as a predictor of in-stent restenosis after successful stent implantation, in 86 patients with unstable angina pectoris. Plasma CRP was measured in all patients before the procedure, and at 48 -72 h and 1, 2 and 3 months post-procedure. An angiographic loss of 50% at follow-up was accepted as in-stent restenosis. We found negative and positive predictive values of the pre-procedural plasma CRP for determining 6-month in-stent restenosis of 34% and 61%, respectively. We also found a strong correlation between the 3-month post-procedural CRP value and 6-month in-stent restenosis; the negative and positive predictive values being 8% and 76%, respectively. In conclusion, we showed that a plasma CRP value > 3 mg/l in the third month after coronary stent implantation was a strong predictor of angiographic in-stent restenosis.
Introduction
There is now considerable evidence from clinical, basic and pathological research that supports the theory that atherosclerosis is an inflammatory disease, and this calls for a change in the way we evaluate and treat acute coronary syndromes. 1 -5 The presence and degree of the inflammatory and procoagulant state, defined by elevated levels of C-reactive protein (CRP), interleukin (IL) 1, IL-6, fibrinogen, tumour necrosis factor-α, adhesion molecules, and plasminogen activator inhibitor, and the composition of the atherosclerotic plaque, have been strongly associated with an increased risk of future cardiac events. 6, 7 Although many markers of inflammation have been associated with adverse cardiovascular outcome, CRP has been evaluated in every clinical phase of coronary disease. 8 In percutaneous coronary revascularization, a hyper-responsive inflammatory response, as defined by elevated CRP levels after balloon angioplasty stent implantation, was recently shown to predict a worse *This paper was presented as a poster at the 74th European Atherosclerosis Congress in Seville, Spain, April 2004. 15 were included in the study if they did not demonstrate any of the exclusion criteria listed prognosis. 9 -13 It has been postulated that this reaction, along with intimal hyperplasia, is responsible for in-stent restenosis. 14 The relationship between the reaction time of the systemic inflammatory response and restenosis of the stent is unclear. This study aimed to determine the relationship between pre-and post-procedural (48 -72 h and 1, 2 and 3 months) CRP values and 6-month restenosis outcomes in patients with unstable angina who were initially treated successfully with coronary artery stent implantation.
Patients and methods

PATIENT GROUP
The study was planned prospectively with inclusion and exclusion criteria being determined in advance. The patient group included patients who were diagnosed with unstable angina pectoris according to the Braunwald classification, 15 who matched the baseline characteristics shown in Table 1 and who had undergone successful stent implantation to one coronary artery. Informed consent was obtained from all patients prior to the study, which was conducted in accordance with the Helsinki Declaration and approved by the ethics committee of Firat University.
Percutaneous intervention was performed under elective conditions after at least 72 h of clinical stabilization. In addition to an oral nitrate, β-blocker, aspirin, statin and low molecule-weight heparin (enoxaparin) treatment, all patients commenced antiplatelet treatment with ticlopidine (500 mg/day) at least 72 h before the operation. Ticlopidine treatment was continued for 1 month. At the end of this period, treatment was discontinued in all patients, although aspirin treatment was continued for an indefinite period of time. Statin treatment was standardized across all patients because of its effect on CRP level. Atorvastatin (40 mg/day) was given to all patients for 1 month, then it was continued at 10 mg/day for 6 months. The patients were evaluated for statin toxicity during routine examinations. Any side-effects caused by stopping the statin treatment were noted. None of the patients was given a glycoprotein IIb/IIIa inhibitor.
CORONARY ANGIOGRAM AND STENT IMPLANTATION
Coronary angiograms were conducted by routine Judkins technique. 16 All patients who were included in the study had atherosclerotic lesions causing 70% or higher luminal constriction in one coronary artery. Pre-and post-coronary angioplasty and follow-up angiograms were analysed using the DCI Host automatic coronary analysis program (Phillips poly C2-OM 2000 MRC DCI, Eindhoven, The I Karaca, K Aydin, M Yavuzkir et al.
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Netherlands), which enables automatic edge detection of the arterial lumen and gives the observer an independent percentage of stenosis. Coronary angiograms were considered for analysis when they were performed with 6 Fr catheters and if the target segment was visualized without superimposition of side branches on an end diastolic frame on two different views. The same views were analysed in each patient on the initial coronary angiogram and at follow-up. Calibration was undertaken on empty catheters, and quantitative determinations of the arterial reference diameter, the minimal lumen diameter (MLD) and the percentage of diameter stenosis were obtained from the average of the measurements in the two views. Measurements at the target site were obtained before and after stent placement and at followup. For complete coronary occlusions, the value of the MLD was assumed to be zero. Late loss (follow-up MLD -post-stent placement MLD) was calculated. The cardiologists who evaluated the angiograms were unaware of the CRP levels of the patients.
Patients selected for percutaneous transluminal coronary angioplasty (PTCA) following coronary angiogram were given intravenous heparin, ensuring that the active clotting time was 300 -350 s. After a 6 F guiding catheter was placed into the coronary orifice, intra-coronary nitroglycerin (100 -200 µg) was given to prevent coronary spasm and to reduce vascular tonus. MLD and lesion length were measured before the operation with quantitative coronary angiography (QCA) by at least two different angiograms. After reference diameter measurements from the distal and proximal ends of the lesion were made, routine PTCA was performed using a monorail balloon catheter. All patients were implanted with stents that were suited to the structure of their vessels. Procedural and electrocardiographic (ECG) differences were recorded.
BLOOD SAMPLES
Angiograms of patients were conducted after a 48 -72 h asymptomatic period without ECG changes. Blood samples were taken during angiography. Angiograms were carried out an average of 5 ± 2 days after the start of symptoms. Pre-procedural samples of blood from all patients were taken from the arterial sheath before the procedure and from the venous blood 48 -72 h post-procedure, and stored at -70°C. All patients were discharged after 72 h. After discharge, patients were examined at the 1-, 2-and 3-month visits in order to record any major cardiac events (major adverse clinical event [MACE] = Q/Non Q myocardial infarction, revascularization, cardiac death). Blood samples were taken at each visit and stored at -70°C. The patients were followed for 6 months, and at the end of this period a control coronary angiogram was performed. According to QCA in the control angiogram, the presence of ≥ 50% constriction in the stent was regarded as an in-stent restenosis.
After all blood samples were collected, plasma CRP was measured by the immunotubidimetric method at the same time in all patients (Alfa Wasserman kit, Schiapparelli Biosystems Inc., Voerden, The Netherlands). A plasma CRP level above 3.0 mg/l was considered high. Troponin T measurements were made in all patients pre-procedure and 6 -24 h post-procedure using the Troponin count device (Roche Diagnostics GmbH, Mannheim, Germany). Patients with a troponin T level > 0.1 mg/dl were excluded from the study to avoid the inflammationtriggering effect of necrotic tissue.
STATISTICAL ANALYSIS
The data were analysed using SPSS ® for Windows program version 10.05. The normal distribution of the data was tested by the Kolmogorov Smirnov test. Normal scattering I Karaca, K Aydin, M Yavuzkir et al. Predictive value of CRP for in-stent restenosis Predictive value of CRP for in-stent restenosis quantitative data were expressed as ± SD. Quantitative data were expressed as median and interquartile range (IQR) and qualitative data were expressed as a percentage. Spearman's correlation analysis was made to determine the correlation between plasma CRP value and the occurrence of restenosis. Pearson correlation analysis was used to evaluate the correlation between plasma CRP value and lumen loss after the follow-up. The Kruskall-Wallis test was employed to assess the relationship between angiographic lesion type and post-procedural CRP values. The Mann-Whitney U-test was utilized to evaluate the relationship between plasma CRP values of patients in group 1 and group 2 at followup. A P-value of < 0.05 was considered statistically significant.
Results
The study evaluated 86 patients (23 female and 63 male) with a mean age of 56.9 ± 9.5 years. The incidence of coronary risk factors at baseline in the patients is shown in Table 2 . The angiographic distribution of lesions was as follows: 38 circumflex, 18 right coronary artery and 30 left anterior descending. According to American Heart Association/American College of Cardiology (AHA/ACC) classification, 17 six lesions (7%) were type A, 32 (37%) were type B and 48 (56%) were type C. The patients were followed for 5.48 ± 1 months (range, 2 -7 months). A MACE was found in a total of six patients (unstable angina pectoris in five cases and acute myocardial infarction in one case). Of these cases, one was given a coronary by-pass operation to the aorta, while the other five underwent percutaneous revascularization. In all patients in whom a MACE occurred, the pre-procedural plasma CRP value was above 3 mg/l. At the end of the follow-up period, a control angiogram was performed in 74/86 patients (86%). The control angiogram revealed that 31 cases (41.9%) had in-stent restenosis. Patients in whom restenosis was found were classified as group 1 (n = 31) and those without restenosis were classified as group 2 (n = 43).
There was no difference between groups 1 and 2 with respect to the time interval and CRP levels from the beginning of symptoms to pre-procedural blood sampling (5.3 ± 2 days versus 5.0 ± 3 days, respectively).
Pre-procedural MLD, lumen diameter within the stent (SMLD) and MLD after the follow-up were as follows: MLD: group 1, median 0.5 mm (IQR, 1 mm) versus group 2, median 0.5 mm (IQR, 1.2 mm); SMLD: group 1, median 3.2 mm (IQR, 0.7 mm) versus group 2 , median 3.2 mm (IQR, 0.5 mm); and followup MLD: group 1, median 0.6 mm (IQR, 1.2 mm) versus group 2, median 3 mm (IQR, 1 mm) (P = 0.005) ( Table 3) . No correlation was found between lumen loss, plasma CRP values in month 1 post-procedure and preprocedural CRP values. However, we found a correlation between the lumen loss at the end of the 6-month follow-up period and the preprocedural CRP values (r = 0.398, P < 0.05). We found a correlation between the postprocedural CRP values in the second and third month and the lumen loss in the 6-month follow-up period (r = 0.319, P = 0.003; r = 0.427, P < 0.001, respectively).
The pre-procedural basal median CRP values of the patients who were found to have restenosis (group 1) were 4 mg/l (IQR, 3 mg/l; range, 0.8 -12 mg/l) compared with those patients without restenosis (group 2), who had a basal median CRP value of 1 mg/l (IQR, 0.8 mg/l; range, 0 -5 mg/l). The difference between groups 1 and 2 in terms of pre-procedural CRP values was statistically significant (P < 0.001). In the Spearman correlation analysis, we found a strong correlation between pre-procedural plasma CRP value and the 6-month restenosis rate (r = 0.698, P < 0.001). When we accepted a plasma CRP level above 3 mg/l as being high, we found that the negative predictive value of the preprocedural plasma CRP value in identifying in-stent restenosis was 34% and the positive predictive value was 61%.
Plasma CRP increased by about 10-fold in both groups 48 -72 h after the percutaneous intervention and there was no statistically significant difference between the groups. The median plasma CRP values 48 -72 h after the procedure were 35 mg/l (IQR, 37 mg/l; range, 5 -74 mg/l) for group 1 and 31 mg/l (IQR, 24 mg/l; range, 9 -73 mg/l) for group 2. There was no correlation between post-procedural (48 -72 h) plasma CRP values and the 6-month restenosis rate.
Regarding the relationship between lesion type, as determined according to the AHA/ACC classification 17 and the plasma CRP value that increased 48 -72 h after stent implantation, it was found that the median post-procedural CRP value was 24 ± 9.4 mg/l in A type lesions (n = 6), 36.3 ± 14.5 mg/l in B type lesions (n = 32), and 33.5 ± 20.4 mg/l in C type lesions (n = 48). There was no statistically significant difference between the angiographic type of the atherosclerotic lesion and plasma CRP value after stent implantation.
Median plasma CRP values 1 month after stent implantation were 11 mg/l (IQR, 15 mg/l; range, 0 -43 mg/l) in group 1 and 9 mg/l (IQR, 20 mg/l; range, 0 -53 mg/l) in group 2. Spearman correlation analysis did not reveal a correlation between plasma CRP value in the first month and the 6-month stent restenosis rate.
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In the second month after stent implantation, median plasma CRP values were 12 mg/l (IQR, 10 mg/l; range, 2 -27 mg/l) in group 1 and 3 mg/l (IQR, 5 mg/l; range, 0 -35 mg/l) in group 2. The difference between the groups was statistically significant (P < 0.01). We found a correlation between plasma CRP value in month 2 and the 6-month in-stent restenosis rate (r = 0.524, P < 0.001).
Median plasma CRP values in the third month post-procedure were 8 mg/l (IQR, 11 mg/l; range, 0 -41 mg/l) in group 1 and 1 mg/l (IQR, 1 mg/l; range, 0 -18 mg/l) in group 2. The difference between the groups was statistically significant (P < 0.01). As a result, there was a strong correlation between the third month plasma CRP values of individuals who had coronary disease and who had had an intra-coronary stent implanted and the 6-month in-stent restenosis rate (r = 0.667, P < 0.001). Plasma CRP values in month 3 were above 3 mg/l, which we accepted as high, in 28/31 patients in group 1. When we regarded this figure as high, we found that the negative predictive value of plasma CRP in the third month in identifying in-stent restenosis was 8% and the positive predictive value was 76%.
Discussion
Our findings show that plasma CRP level increases in patients with unstable angina pectoris (UAP) following the trauma that develops as a result of PTCA. Our findings are consistent with the literature in this area. 9, 11, 13, 18 We have shown that after PTCA, the plasma CRP value increases more than 10-fold. The increase observed in this acute phase reactant may be attributed to damage to the coronary plaques. Azar et al. 11 reported that in their series plasma CRP levels increased around six-fold following PTCA. This increase was less than that observed in our study of patients with UAP, and their finding might be indicative of a milder grade inflammation in their patients who, in contrast to ours, were all diagnosed with stable angina pectoris (SAP). It has been suggested in previous studies that stent implantation in patients with UAP leads to a higher inflammatory response than that observed in patients with SAP. 9, 13 Another reason why we observed a greater increase in plasma CRP value following PTCA may be that the coronary lesions in our cases were more active. For instance, the lesions in our patients might contain more oxidized low-density lipoprotein cholesterol, which can directly trigger acute phase protein production. 19 Lesions might also contain more virus-infected cells, leading to the activation of mononuclear cells and an increase in cytokine production. 20 Coronary lesions that contain a higher number of inflammatory cells such as lymphocytes, monocytes and macrophages might also increase plasma CRP levels. 21, 22 Attributing the increase in plasma CRP to the PTCA procedure damaging the coronary plaques might be incorrect, since increases in plasma CRP have been reported following the minimal trauma induced by cardiac catheterization without PTCA in patients with UAP. 9 We demonstrated that plasma CRP measured 48 -72 h after percutaneous intervention was not predictive for restenosis at the 6-month follow-up. Azar et al. 11 found restenosis in three of 42 cases after the 6-month follow-up, and observed significantly higher plasma CRP values after the procedure in two of these cases (108 mg/l and 60 mg/l). However, this study measured both creatine kinase MB and troponin T cardiac enzyme levels, but did not exclude patients if their levels of these enzymes were high. 11 We think it is possible that the minimal cardiac Predictive value of CRP for in-stent restenosis necrosis that might occur after the procedure could cause both an important increase in plasma CRP and an increase in the follow-up restenosis rate. The fact that pre-procedural plasma CRP values were high in these two patients may be a reason for the postprocedural increase. 11 Azar et al. 11 did not perform routine control angiography at month 6; coronary angiography was only performed in one case because of acute myocardial infarction and in one other case due to severe angina pectoris, and that was how restenosis was identified. It is possible that other cases of (silent) restenosis might have been overlooked during the study.
Our findings suggest that high plasma CRP level before the percutaneous intervention was correlated with the 6-month restenosis rate. Walter et al. 14 also showed in their 276-case series that pre-procedural CRP level was a predictor of 6-month restenosis, which is consistent with our data. Versaci et al. 23 reported that pre-procedural CRP level correlated with cardiac events after coronary stent implantation in a 12-month clinical follow-up. In the light of these findings, we can say that pre-procedural systemic inflammatory activity works together with the proliferative response that is seen after successful stent implantation, to cause restenosis.
Our observations suggest that the type of pre-procedural angiographic lesion identified according to the AHA/ACC classification 17 did not affect the plasma CRP level measured 48 -72 h after the procedure. Gottsauner-Wolf et al. 24 reported that stent implantation applied to angiographic C type lesions led to a greater increase in plasma CRP than A and B type lesions. It is known that follow-up restenosis is higher in stent implantations to angiographic C type lesions. In our findings, plasma CRP measured 48 -72 h after the procedure did not affect the 6-month restenosis rate. The fact that we found similarly high plasma CRP levels in A, B and C type lesions supports this observation. In addition, it has previously been shown that plasma CRP values may increase after coronary angiography without rupture of the ateron plaque. 9 Previous studies have also reported that there was a correlation between clinical severity in cases that were diagnosed as UAP according to the Braunwald classification 15 and post-procedural CRP value. 13 In light of these data, we believe that randomized studies with larger numbers of cases should be conducted to determine the effect that the type of angiographic lesion, as defined by the AHA/ACC classification, 17 has on postprocedural CRP value.
In the follow-up of our cases we found that the presence of inflammatory activation measured by the elevation in plasma CRP at months 2 and 3 correlated with 6-month restenosis. In our groups, consisting of cases with and without restenosis, we identified differences in plasma CRP values in these months that were statistically significant. In particular, 90.3% of the cases who developed restenosis had high 3-month CRP values of > 3 mg/l. In conclusion, we showed that a plasma CRP value > 3 mg/l in the third month after the coronary stent implantation was a strong predictor of angiographic in-stent restenosis.
